LncRNA-ATB Promotes the Tumorigenesis of Ovarian Cancer via Targeting miR-204-3p
Authors Yuan D, Qian H, Guo T, Ye J, Jin C, Liu X, Jiang L, Wang X, Lin M, Yu H
Received 10 September 2019
Accepted for publication 22 December 2019
Published 20 January 2020 Volume 2020:13 Pages 573—583
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Leo Jen-Liang Su
Donglan Yuan, 1,* Hua Qian, 1,* Ting Guo, 2 Jun Ye, 2 Chunyan Jin, 2 Xia Liu, 1 Li Jiang, 1 Xiaoxiang Wang, 1 Mei Lin, 3 Hong Yu 4
1Department of Obstetrics and Gynecology, Taizhou People’s Hospital, Taizhou, Jiangsu, People’s Republic of China; 2Center for Molecular Medicine, Taizhou People’s Hospital, Taizhou, Jiangsu, People’s Republic of China; 3Scientific Research Office, Taizhou People’s Hospital, Taizhou, Jiangsu, People’s Republic of China; 4Department of Pathology, Taizhou People’s Hospital, Taizhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hong Yu
Department of Pathology, Taizhou People’s Hospital, 399 Hailing Road, Taizhou, Jiangsu 225300, People’s Republic of China
Background: Ovarian cancer ranks fifth among the most prevalent cancer type in females all over the world. It is the second most frequent malignant tumor which accounts for 3% of cancer in females. Therefore, to explore the mechanism of carcinogenesis in ovarian cancer is important to develop new treatment methods. It has been previously found that lncRNA-ATB could promote the tumorigenesis of malignant tumors. However, the role of lncRNA-ATB during the progression of ovarian cancer remains unclear.
Methods: Gene expressions in tissues or cells were detected by using qRT-PCR. Western blot was performed to investigate the protein expressions in ovarian cancer cells. Cell apoptosis was tested by flow cytometry. Moreover, the correction between lncRNA-ATB and miR-204-3p was examined by Dual-luciferase reporter assay and RNA pulldown. Cell proliferation and invasion were detected by CCK-8, Ki-67 staining and transwell assay, respectively. Finally, xenograft mice model was established to confirm the result of in vitro experiments.
Results: LncRNA-ATB silencing significantly inhibited the proliferation and induced apoptosis of ovarian cancer cells. In addition, luciferase activity suggested that lncRNA-ATB negatively regulated miR-204-3p in ovarian cancer. Besides, Nidogen 1 (NID1) was the direct target of miR-204-3p. Overexpression of NID1 could notably reverse the inhibitory effect of lncRNA-ATB knockdown on the progression of ovarian cancer. Finally, lncRNA-ATB silencing notably attenuated the severity of ovarian cancer in vivo.
Conclusion: Downregulation of lncRNA-ATB significantly inhibited the tumorigenesis of ovarian cancer in vitro and in vivo, which may serve as a potential novel target for the treatment of ovarian cancer.
Keywords: ovarian cancer, lncRNA-ATB, miR-204-3p, NID1
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]